Tazemetostat for the Treatment of Relapsed/Refractory Follicular Lymphoma

• Status: Not yet recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

Treating Relapsed/Refractory Follicular Lymphoma with Tazemetostat

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hutchison Medipharma Limited

Criteria

Inclusion Criteria:

1. Fully aware this study and signed the informed consent form in voluntary manner, and willing and able to comply with the study procedure;

2. Age ≥18 years;

3. Patients with histologically confirmed R/R FL (Grades 1, 2, 3a)

4. Patients must have one measurable lesion

5. Life expectancy ≥ 12 weeks;

6. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2

7. Adequate bone marrow function, renal function and hepatic function:

8. Currently human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) or cytomegalovirus (CMV) is inactive:

9. Female patients of childbearing potential must agree to adopt dual contraceptive method

Exclusion Criteria:

1. Previous use of Tazemetostat or other EZH2 inhibitors;

2. Patients with invasion of lymphoma to the central nervous system (CNS) or the pia mater;

3. Previous bone marrow malignancies,

4. Abnormalities associated with MDS and myeloproliferative neoplasms observed by cytogenetic testing and DNA sequencing;